Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?

DOI Web Site 被引用文献1件
  • A. Kontou
    1st Department of Neonatology, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece
  • K. Sarafidis
    1st Department of Neonatology, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece
  • O. Begou
    Laboratory of Analytical Chemistry, School of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • H. G. Gika
    Department of Medicine, Laboratory of Forensic Medicine & Toxicology, Aristotle University School of Health Sciences, Thessaloniki, Greece
  • A. Tsiligiannis
    Department of Pharmacy, University of Athens, Athens, Greece
  • K. Ogungbenro
    Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
  • A. Dokoumetzidis
    Department of Pharmacy, University of Athens, Athens, Greece
  • E. Agakidou
    1st Department of Neonatology, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece
  • E. Roilides
    Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece

説明

<jats:p>Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the currently recommended dosing regimen in term and preterm neonates. By using an optimal design approach, a prospective PK study was designed and implemented in 60 neonates with postmenstrual ages (PMA) of 26 to 43 weeks. A loading dose of 16 mg/kg was administered at day 1, followed by a maintenance dose of 8 mg/kg daily. Plasma concentrations were quantified by high-pressure liquid chromatography–mass spectrometry.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ